Page 205 - Read Online

Page 6 of 10 Zhao et al. Hepatoma Res 2019;5:17 I http://dx.doi.org/10.20517/2394-5079.2018.116

Figure 4. Meta-analysis of the one-year survival rate in 13 studies comparing transarterial chemoembolization (TACE) plus stereotactic
body radiation therapy (SBRT) with TACE or SBRT monotherapy for intermediate-to advanced-stage hepatocellular carcinoma patients

Figure 5. Meta-analysis of the two-year survival in 6 studies comparing transarterial chemoembolization (TACE) plus stereotactic body
radiation therapy (SBRT) with TACE or SBRT monotherapy for intermediate-to advanced-stage hepatocellular carcinoma patients

The results showed that negative conversion rate of AFP of the combined therapy group (TACE + SBRT)
was significantly higher than that of the monotherapy group (RR = 1.756, 95%CI: 1.502-2.059, P < 0.001). The
Egger test (P = 0.175) and the Begg test (P = 0.707) revealed no publication bias. The result of the nagative
conversion rate of AFP was shown in [Figure 6].

DISCUSSION
This current meta-analysis aimed to assess the validity and safety of SBRT combined with TACE for patients
in intermediate-to advanced-stage HCC. The pooled results showed that TACE plus SBRT notably ameliorated
the total survival rates of half-year, one-year and two-year (P < 0.05). Combination treatment of SBRT and
TACE were also benefited to the negative conversion rate of AFP and the total effective rate (P < 0.05). The
results revealed that SBRT combined with TACE had superior efficacy than that of SBRT or TACE alone for
HCC patients in intermediate-to advanced-stage.